Article: Nicotinamide Riboside and Metabolic Cofactors Improve Gut Health in Fatty Liver Disease: Preclinical Findings

PrevNext
Digestive/Gut Health Liver Disease Liver Health Preclinical

Nicotinamide Riboside and Metabolic Cofactors Improve Gut Health in Fatty Liver Disease: Preclinical Findings

Synopsis

The gut barrier controls what passes into the body and protects organs like the liver. An unhealthy diet and lifestyle cause gut microbiome imbalances (dysbiosis) and gut barrier damage, which worsen non-alcoholic fatty liver disease (NAFLD). This study tested a combination of metabolic cofactors (betaine, N-acetylcysteine, L-carnitine, nicotinamide riboside) in mice with diet-induced NAFLD. Treatment improved gut structure, reduced gut leakiness, lowered inflammation, and increased gut cell growth. It also changed gut bacteria composition and beneficial short-chain fatty acids. These effects helped slow NAFLD progression by improving gut-liver communication.

Journal

International Journal of Molecular Sciences

Share

Read more

Healthy Aging & Longevity

Comparison of Metformin and Nicotinamide Riboside in Reducing Tissue Aging: Preclinical Findings

SynopsisMetformin (MET) and nicotinamide riboside (NR) both have potential anti-aging effects, but how they work in different tissues isn't fully clear. This study showed that MET and NR reduce sig...

Read more
Alzheimer's Disease

Nicotinamide Riboside Enhances Brain Enzymes to Combat Alzheimer’s Pathology: Preclinical Findings

SynopsisSIRT3 is a mitochondrial enzyme that improves cell function. Deleting SIRT3 causes brain mitochondrial problems and worsens Alzheimer's disease (AD) features in mice, including insulin resi...

Read more